secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-037192
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits
-------------------------------------------------------------------------------

- Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).
- clonoSEQ test volume +52% to 13,665 tests delivered.
- Net loss $47.8M vs $52.1M YoY; adjusted EBITDA loss $24.8M vs $33.1M.
- Full-year 2023 revenue guidance reiterated at $205-215M; operating expenses expected below 2022's $385.5M.
- Nitin Sood, Chief Commercial Officer of MRD, resigns effective Aug 15; Susan Bobulsky assumes additional responsibilities, reports to CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/adpt-20230728.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer